全球唯一!康方生物三抗获批,多抗赛道的“达尔文游戏”进入深水区

药闻天下
Mar 11

就在几天前(2026年3月9日),CDE官网悄然更新了一条重磅信息:康方生物自主研发的注射用AK150正式获批临床,适应症剑指晚期实体瘤。作为全球唯一一款同时靶向LILRB1、LILRB2和CSF1R的在研三抗产品。有意思的是,在这则新闻的评论区,有读者冷不丁地留了一句言:“四抗早获批临床了。”这句话非常精准地刺穿了当前中国创新药行业的某种群体焦虑——在单抗红海化、双抗即将“卷”成标配的今天,靶点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10